Type 2 diabetes and cardiovascular disease: Getting to the fat of the matter

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 1, 2007, Pages 113-132

  Goralski, Kerry B ^a,b   Sinal, Christopher J ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Acylation stimulating protein; Adipocyte; Adipokine; Adiponectin; Adipose; Adrenomedullin; Atherosclerosis; Diabetes; Leptin; Obesity; Plasminogen activator inhibitor 1; Resistin; Retinol binding protein 4; Tumour necrosis factor alpha

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPONECTIN; ADIPSIN; ADRENOMEDULLIN; ANGIOTENSIN II; CYTOKINE; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RETINOL BINDING PROTEIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISFATIN; COMPLEMENT C3A, DES ARG (77); COMPLEMENT C3A, DES-ARG-(77); COMPLEMENT COMPONENT C3A; COMPLEMENT FACTOR D; PRE B CELL COLONY ENHANCING FACTOR, HUMAN; PRE-B-CELL COLONY-ENHANCING FACTOR, HUMAN; RBP4 PROTEIN, HUMAN;

ADIPOSE TISSUE; BLOOD PRESSURE; CANADA; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ANIMAL; COMPLEMENT ACTIVATION; FIBRINOLYSIS; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADIPONECTIN; ADIPOSE TISSUE; ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT FACTOR D; CYTOKINES; DIABETES MELLITUS, TYPE 2; FIBRINOLYSIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LEPTIN; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN-ANGIOTENSIN SYSTEM; RESISTIN; RETINOL-BINDING PROTEINS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34250823044     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y06-092     Document Type: Review

References (252)

1. Ajuwon, K.M., and Spurlock, M.E. 2005. Adiponectin inhibits LPS-induced NF-κB activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288: R1220-R1225.
2. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., et al. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257: 79-83. doi:10.1006/bbrc.1999.0255.
3. Arner, P. 2006. Visfatin - a true or false trail to type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91: 28-30. doi:10.1210/jc.2005- 2391.
4. Asilmaz, E., Cohen, P., Miyazaki, M., Dobrzyn, P., Ueki, K., Fayzikhodjaeva, G., et al. 2004. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J. Clin. Invest. 113: 414-424. doi:10.1172/JCI200419511.
5. Aso, Y., Matsumoto, S., Fujiwara, Y., Tayama, K., Inukai, T., and Takemura, Y. 2002. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism, 51: 471-476. doi:10.1053/meta.2002. 31334.
6. Avellone, G., Di Garbo, V., Cordova, R., Rotolo, G., Abruzzese, G., Raneli, G., De Simone, R., and Bompiani, G.D. 1994. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Res. 25: 85-92.
7. Banerjee, R.R., Rangwala, S.M., Shapiro, J.S., Rich, A.S., Rhoades, B., Qi, Y., et al. 2004. Regulation of fasted blood glucose by resistin. Science (Washington, D.C.), 303: 1195-1198. doi:10.1126/science.1092341.
8. Barb, D., Wadhwa, S.G., Kratzsch, J., Gavrila, A., Chan, J.L., Williams, C.J., Karchmer, A.W., and Mantzoros, C.S. 2005. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J. Clin. Endocrinol. Metab. 90: 5324-5328. doi:10.1210/jc.2005- 0742.
9. Bauer, J., Lengyel, G., Bauer, T.M., Acs, G., and Gerok, W. 1989. Regulation of interleukin-6 receptor expression in human monocytes and hepatocytes. FEBS Lett. 249: 27-30. doi.10.1016/0014-5793(89)80008-0.
10. Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M.R., Stumvoll, M., and Bluher, M. 2005. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes, 54: 2911-2916.
11. Bernstein, L.E., Berry, J., Kim, S., Canavan, B., and Grinspoon, S.K. 2006. Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 166: 902-908. doi:10.1001/archinte.166.8.902.
12. Beutler, B., Greenwald, D., Hulmes, J.D., Chang, M., Pan, Y.C., Mathison, J., Ulevitch, R., and Cerami, A. 1985a. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (London), 316: 552-554. doi:10.1038/316552a0.
13. Beutler, B.A., Milsark, I.W., and Cerami, A. 1985b. Cachectin/ tumor necrosis factor: production, distribution, and metabolic fate in vivo. J. Immunol. 135: 3972-3977.
14. Birmingham, C.L., Muller, J.L., Palepu, A., Spinelli, J.J., and Anis, A.H. 1999. The cost of obesity in Canada. CMAJ, 160: 483-488.
15. Bouchard, L., Weisnagel, S.J., Engert, J.C., Hudson, T.J., Bouchard, C., Vohl, M.C., and Perusse, L. 2004. Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Quebec Family Study. J. Endocrinol. Invest. 27: 1003-1009.
16. Brendle, D.C., Joseph, L.J., Corretti, M.C., Gardner, A.W., and Katzel, L.I. 2001. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am. J. Cardiol. 87: 324-329. doi:10.1016/S0002-9149(00)01367-9.
17. Brown, R., Wiesner, G., Ur, E., and Wilkinson, M. 2005. Pituitary resistin gene expression is upregulated in vitro and in vivo by dexamethasone but is unaffected by rosiglitazone. Neuroendocrinology, 81: 41-48. doi:10.1159/000084873.
18. Bullo, M., Garcia-Lorda, P., Peinado-Onsurbe, J., Hernandez, M., Del Castillo, D., Argiles, J.M., and Salas-Salvado, J. 2002. TNFalpha expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis. Int. J. Obes. Relat. Metab. Disord. 26: 652-658. doi:10.1038/sj.ijo.0801977.
19. Bullo, M., Garcia-Lorda, P., Megias, I., and Salas-Salvado, J. 2003. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res. 11: 525-531.
20. Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., and Burn, P. 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science (Washington, D.C.), 269: 546-549. doi:10.1126/science.7624778.
21. Canning, P.M., Courage, M.L., and Frizzell, L.M. 2004. Prevalence of overweight and obesity in a provincial population of Canadian preschool children. CMAJ, 171: 240-242.
22. Cannon, B., and Nedergaard, J. 2004. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84: 277-359. doi:10.1152/physrev.00015.2003.
23. Caro, J.F., Kolaczynski, J.W., Nyce, M.R., Ohannesian, J.P., Opentanova, I., Goldman, W.H., et al. 1996. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet, 348: 159-161. doi:10.1016/S0140-6736(96)03173-X.
24. Carvalho, E., Kotani, K., Peroni, O.D., and Kahn, B.B. 2005. Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am. J. Physiol. Endocrinol. Metab. 289: E551-E561. doi:10.1152/ajpendo.00116.2005.
25. Chan, T.F., Chen, Y.L., Lee, C.H., Chou, F.H., Wu, L.C., Jong, S.B., and Tsai, E.M. 2006. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J. Soc. Gynecol. Investig. 13: 364-367.
26. Chen, H., Charlat, O., Tartaglia, L.A., Woolf, E.A., Weng, X., Ellis, S.J., et al. 1996. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell, 84: 491-495. doi:10.1016/S0092-8674(00)81294-5.
27. Chen, M.P., Chung, F.M., Chang, D.M., Tsai, J.C., Huang, H.F., Shin, S.J., and Lee, Y.J. 2006. Elevated plasma level of visfatin/ pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91: 295-299. doi:10.1210/jc.2005-1475.
28. Choi, K.C., Ryu, O.H., Lee, K.W., Kim, H.Y., Seo, J.A., Kim, S.G., et al. 2005. Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats. Biochem. Biophys. Res. Commun. 336: 747-753. doi:10.1016/j.bbrc.2005.08.203.
29. Choy, L.N., Rosen, B.S., and Spiegelman, B.M. 1992. Adipsin and an endogenous pathway of complement from adipose cells. J. Biol. Chem. 267: 12736-12741.
30. Cianflone, K., and Maslowska, M. 1995. Differentiation-induced production of ASP in human adipocytes. Eur. J. Clin. Invest. 25: 817-825.
31. Cianflone, K., Rodriguez, M.A., Walsh, M., Vu, H., and Sniderman, A.D. 1988. The effect of a plasma protein fraction on lipid synthesis in cultured skin fibroblasts from normals and patients with hyperapobetalipoproteinemia. Clin. Invest. Med. 11: 99-107.
32. Cianflone, K., Vu, H., Walsh, M., Baldo, A., and Sniderman, A. 1989a. Metabolic response of acylation stimulating protein to an oral fat load. J. Lipid Res. 30: 1727-1733.
33. Cianflone, K.M., Sniderman, A.D., Walsh, M.J., Vu, H.T., Gagnon, J., and Rodriguez, M.A. 1989b. Purification and characterization of acylation stimulating protein. J. Biol. Chem. 264: 426-430.
34. Cianflone, K., Roncari, D.A., Maslowska, M., Baldo, A., Forden, J., and Sniderman, A.D. 1994. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry, 33: 9489-9495. doi:10.1021/bi00198a014.
35. Cianflone, K., Kalant, D., Marliss, E.B., Gougeon, R., and Sniderman, A.D. 1995a. Response of plasma ASP to a prolonged fast. Int. J. Obes. Relat. Metab. Disord. 19: 604-609.
36. Cianflone, K., Maslowska, M., and Sniderman, A. 1995b. The acylation stimulating protein-adipsin system. Int. J. Obes. Relat. Metab. Disord. 19(Suppl. 1): S34-S38.
37. Cianflone, K., Xia, Z., and Chen, L.Y. 2003. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta, 1609: 127-143.
38. Cianflone, K., Zakarian, R., Couillard, C., Delplanque, B., Despres, J.P., and Sniderman, A. 2004. Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance. J. Lipid Res. 45: 124-131.
39. Cianflone, K., Lu, H., Smith, J., Yu, W., and Wang, H. 2005. Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children. Clin. Endocrinol. (Oxf.), 62: 567-572. doi.10.1111/j.1365-2265.2005.02260.x.
40. Cinti, S. 2005. The adipose organ. Prostaglandins Leukot. Essent. Fatty Acids, 73: 9-15. doi.10.1016/j.plefa.2005.04.010.
41. Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., et al. 2005. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46: 2347-2355.
42. Clausen, J.O., Borch-Johnsen, K., Ibsen, H., Bergman, R.N., Hougaard, P., Winther, K., and Pedersen, O. 1996. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and lifestyle factors. J. Clin. Invest. 98: 1195-1209.
43. Coleman, D.L. 1973. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia, 9: 294-298. doi:10.1007/BF01221857.
44. Coleman, D.L. 1978. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia, 14: 141-148. doi:10.1007/BF00429772.
45. Coleman, D.L., and Hummel, K.P. 1969. Effects of parabiosis of normal with genetically diabetic mice. Am. J. Physiol. 217: 1298-1304.
46. Combs, T.P., Berg, A.H., Rajala, M.W., Klebanov, S., Iyengar, P., Jimenez-Chillaron, J.C., et al. 2003. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes, 52: 268-276.
47. Cormier-Regard, S., Nguyen, S.V., and Claycomb, W.C. 1998. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J. Biol. Chem. 273: 17787-17792. doi:10.1074/jbc.273.28.17787.
48. Cornelius, P., Enerback, S., Bjursell, G., Olivecrona, T., and Pekala, P.H. 1988. Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor. Biochem. J. 249: 765-769.
49. Curat, C.A., Miranville, A., Sengenes, C., Diehl, M., Tonus, C., Busse, R., and Bouloumie, A. 2004. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes, 53: 1285-1292.
50. Curat, C.A., Wegner, V., Sengenes, C., Miranville, A., Tonus, C., Busse, R., and Bouloumie, A. 2006. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 49: 744-747. doi:10.1007/s00125-006-0173-z.
51. Czubryt, M.P., Espira, L., Lamoureux, L., and Abrenica, B. 2006. The role of sex in cardiac function and disease. Can. J. Physiol. Pharmacol. 84: 93-109. doi:10.1139/y05-151.
52. Dandona, P., Weinstock, R., Thusu, K., Abdel-Rahman, E., Aljada, A., and Wadden, T. 1998. Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 83: 2907-2910. doi:10.1210/jc.83.8.2907.
53. Darimont, C., Vassaux, G., Ailhaud, G., and Negrel, R. 1994. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology, 135: 2030-2036. doi:10.1210/en.135.5.2030.
54. Di Gregorio, G.B., Hensley, L., Lu, T., Ranganathan, G., and Kern, P.A. 2004. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am. J. Physiol. Endocrinol. Metab. 287: E182-E187. doi:10.1152/ajpendo.00189.2003.
55. Dzielinska, Z., Januszewicz, A., Wiecek, A., Demkow, M., Makowiecka-Ciesla, M., Prejbisz, A., et al. 2003. Decreased plasma concentration of a novel anti-inflammatory protein - adiponectin - in hypertensive men with coronary artery disease. Thromb. Res. 110: 365-369. doi:10.1016/j. thromres.2003.08. 004.
56. Eriksson, P., Reynisdottir, S., Lonnqvist, F., Stemme, V., Hamsten, A., and Arner, P. 1998. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia, 41: 65-71. doi:10.1007/s001250050868.
57. Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., and Bahouth, S.W. 2004. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 145: 2273-2282. doi:10.1210/en.2003-1336.
58. Fasshauer, M., Kralisch, S., Klier, M., Lossner, U., Bluher, M., Klein, J., and Paschke, R. 2003. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 301: 1045-1050. doi:10.1016/S0006-291X(03)00090-1.
59. Folsom, A.R., Qamhieh, H.T., Wing, R.R., Jeffery, R.W., Stinson, V.L., Kuller, L.H., and Wu, K.K. 1993. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler. Thromb. 13: 162-169.
60. Frederich, R.C., Jr., Kahn, B.B., Peach, M.J., and Flier, J.S. 1992. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension, 19: 339-344.
61. Fried, S.K., Bunkin, D.A., and Greenberg, A.S. 1998. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83: 847-850. doi:10.1210/jc.83.3.847.
62. Friedman, J.M., and Halaas, J.L. 1998. Leptin and the regulation of body weight in mammals. Nature (London), 395: 763-770. doi:10.1038/27376.
63. Fukai, N., Yoshimoto, T., Sugiyama, T., Ozawa, N., Sato, R., Shichiri, M., and Hirata, Y. 2005. Concomitant expression of adrenomedullin and its receptor components in rat adipose tissues. Am. J. Physiol. Endocrinol. Metab. 288: E56-E62.
64. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., et al. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (Washington, D.C.), 307: 426-430. doi:10.1126/science.1097243.
65. Ganter, U., Arcone, R., Toniatti, C., Morrone, G., and Ciliberto, G. 1989. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8: 3773-3779.
66. Garcia-Unzueta, M.T., Montalban, C., Pesquera, C., Berrazueta, J.R., and Amado, J.A. 1998. Plasma adrenomedullin levels in type 1 diabetes. Relationship with clinical parameters. Diabetes Care, 21: 999-1003.
67. Gavrila, A., Chan, J.L., Yiannakouris, N., Kontogianni, M., Miller, L.C., Orlova, C., and Mantzoros, C.S. 2003. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J. Clin. Endocrinol. Metab. 88: 4823-4831. doi:10.1210/jc.2003-030214.
68. Ghosh, S., Singh, A.K., Aruna, B., Mukhopadhyay, S., and Ehtesham, N.Z. 2003. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene, 305: 27-34. doi:10.1016/S0378-1119(02)01213-1.
69. Goldstein, B.J., and Scalia, R. 2004. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 89: 2563-2568. doi:10.1210/jc.2004-0518.
70. Gorstein, J., and Grosse, R.N. 1994. The indirect costs of obesity to society. Pharmacoeconomics, 5: 58-61.
71. Graham, T.E., Yang, Q., Bluher, M., Hammarstedt, A., Ciaraldi, T.P., Henry, R.R., et al. 2006. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354: 2552-2563. doi:10.1056/NEJMoa054862.
72. Greenberg, A.S., Nordan, R.P., McIntosh, J., Calvo, J.C., Scow, R.O., and Jablons, D. 1992. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 52: 4113-4116.
73. Grinspoon, S., Gulick, T., Askari, H., Landt, M., Lee, K., Anderson, E., et al. 1996. Serum leptin levels in women with anorexia nervosa. J. Clin. Endocrinol. Metab. 81: 3861-3863. doi:10.1210/jc.81.11.3861.
74. Haider, D.G., Schindler, K., Schaller, G., Prager, G., Wolzt, M., and Ludvik, B. 2006. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab. 91: 1578-1581. doi:10.1210/jc.2005-2248.
75. Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz, D., et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science (Washington, D.C.), 269: 543-546. doi:10.1126/science.7624777.
76. Hammarstedt, A., Pihlajamaki, J., Rotter Sopasakis, V., Gogg, S., Jansson, P.A., Laakso, M., and Smith, U. 2006. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J. Clin. Endocrinol. Metab. 91: 1181-1184.
77. Hayashi, M., Shimosawa, T., Isaka, M., Yamada, S., Fujita, R., and Fujita, T. 1997. Plasma adrenomedullin in diabetes. Lancet, 350: 1449-1450. doi:10.1016/S0140-6736(05)64211-0.
78. He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., et al. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100: 15712-15717. doi:10.1073/pnas.2536828100.
79. Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G., and Schaper, F. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374: 1-20. doi:10.1042/BJ20030407.
80. Heinrich, P.C., Castell, J.V., and Andus, T. 1990. Interleukin-6 and the acute phase response. Biochem. J. 265: 621-636.
81. Heymsfield, S.B., Greenberg, A.S., Fujioka, K., Dixon, R.M., Kushner, R., Hunt, T., et al. 1999. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA, 282: 1568-1575. doi:10.1001/jama.282.16.1568.
82. Hirata, Y., Mitaka, C., Sato, K., Nagura, T., Tsunoda, Y., Amaha, K., and Marumo, F. 1996. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J. Clin. Endocrinol. Metab. 81: 1449-1453. doi:10.1210/jc.81.4.1449.
83. Hotamisligil, G.S., Arner, P., Caro, J.F., Atkinson, R.L., and Spiegelman, B.M. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
84. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (Washington, D.C.), 259: 87-91. doi:10.1126/science. 7678183.
85. Hotamisligil, G.S., Peraldi, P., Budavari, A., Ellis, R., White, M.F., and Spiegelman, B.M. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science (Washington, D.C.), 271: 665-668. doi:10.1126/science.271.5249. 665.
86. Hu, E., Liang, P., and Spiegelman, B.M. 1996. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271: 10697-10703.
87. Huang, L., Wang, Z., and Li, C. 2001. Modulation of circulating leptin levels by its soluble receptor. J. Biol. Chem. 276: 6343-6349. doi:10.1074/jbc.M009795200.
88. Hukshorn, C.J., van Dielen, F.M., Buurman, W.A., Westerterp-Plantenga, M.S., Campfield, L.A., and Saris, W.H. 2002. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int. J. Obes. Relat. Metab. Disord. 26: 504-509. doi:10.1038/sj.ijo. 0801952.
89. Itoh, K., Imai, K., Masuda, T., Abe, S., Tanaka, M., Koga, R., et al. 2002. Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens. Res. 25: 881-886. doi:10.1291/hypres.25. 881.
90. Iwaki, M., Matsuda, M., Maeda, N., Funahashi, T., Matsuzawa, Y., Makishima, M., and Shimomura, I. 2003. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 52: 1655-1663.
91. Iwasaki, H., Eguchi, S., Shichiri, M., Marumo, F., and Hirata, Y. 1998. Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. Endocrinology, 139: 3432-3441. doi:10.1210/en.139.8.3432.
92. Janke, J., Engeli, S., Gorzelniak, K., Luft, F.C., and Sharma, A.M. 2002. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 10: 1-5.
93. Jougasaki, M., Wei, CM., Heublein, D.M., Sandberg, S.M., and Burnett, J.C., Jr. 1995. Immunohistochemical localization of adrenomedullin in canine heart and aorta. Peptides, 16: 773-775. doi:10.1016/0196-9781(95)00011-8.
94. Kalant, D., Cain, S.A., Maslowska, M., Sniderman, A.D., Cianflone, K., and Monk, P.N. 2003. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J. Biol. Chem. 278: 11123-11129. doi:10.1074/jbc.M206169200.
95. Kalant, D., MacLaren, R., Cui, W., Samanta, R., Monk, P.N., Laporte, S.A., and Cianflone, K. 2005. C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 280: 23936-23944. doi:10.1074/jbc.M406921200.
96. Kamin, D., Hadigan, C., Lehrke, M., Mazza, S., Lazar, M.A., and Grinspoon, S. 2005. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J. Clin. Endocrinol. Metab. 90: 3423-3426. doi:10.1210/jc.2005-0287.
97. Karlsson, C., Lindell, K., Ottosson, M., Sjostrom, L., Carlsson, B., and Carlsson, L.M. 1998. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 83: 3925-3929. doi:10.1210/jc.83.11.3925.
98. Kato, H., Shichiri, M., Marumo, F., and Hirata, Y. 1997. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology, 138: 2615-2620. doi:10.1210/en.138.6.2615.
99. Kato, K., Yamada, D., Midorikawa, S., Sato, W., and Watanabe, T. 2000. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism, 49: 662-665. doi:10.1016/S0026-0495(00)80045-1.
100. Kato, J., Kitamura, K., Uemura, T., Kuwasako, K., Kita, T., Kangawa, K., and Eto, T. 2002. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens. Res. 25: 887-892. doi:10.1291/hypres.25.887.
101. Katsuki, A., Sumida, Y., Murata, K., Furuta, M., Araki-Sasaki, R., Tsuchihashi, K., et al. 2000. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes. Metab. 2: 189-191. doi:10.1046/j.1463-1326.2000.00072.x
102. Katzmarzyk, P.T., and Janssen, I. 2004. The economic costs associated with physical inactivity and obesity in Canada: an update. Can. J. Appl. Physiol. 29: 90-115.
103. Katzmarzyk, P.T., and Mason, C. 2006. Prevalence of class I, II and III obesity in Canada. CMAJ, 174: 156-157.
104. Kern, P.A., Ranganathan, S., Li, C., Wood, L., and Ranganathan, G. 2001. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280: E745-E751.
105. Kern, P.A., Saghizadeh, M., Ong, J.M., Bosch, R.J., Deem, R., and Simsolo, R.B. 1995. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95: 2111-2119.
106. Kim, H.J., Higashimori, T., Park, S.Y., Choi, H., Dong, J., Kim, Y.J., et al. 2004. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes, 53: 1060-1067.
107. Kim, J.K., Gavrilova, O., Chen, Y., Reitman, M.L., and Shulman, G.I. 2000. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275: 8456-8460. doi:10.1074/jbc.275.12.8456.
108. Kim, W., Moon, S.O., Sung, M.J., Kim, S.H., Lee, S., So, J.N., and Park, S.K. 2003. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J. 17: 1937-1939.
109. Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., and Eto, T. 1993. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192: 553-560. doi:10.1006/bbrc.1993.1451.
110. Klover, P.J., Zimmers, T.A., Koniaris, L.G., and Mooney, R.A. 2003. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes, 52: 2784-2789.
111. Klover, P.J., Clementi, A.H., and Mooney, R.A. 2005. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology, 146: 3417-3427. doi:10.1210/en.2004-1468.
112. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., and Nathan, D.M. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346: 393-403.
113. Kohler, H.P., and Grant, P.J. 2000. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342: 1792-1801. doi:10.1056/NEJM200006153422406.
114. Kopelman, P.G. 2000. Obesity as a medical problem. Nature (London), 404: 635-643.
115. Kurscheid, T., and Lauterbach, K. 1998. The cost implications of obesity for health care and society. Int. J. Obes. Relat. Metab. Disord. 22: Suppl. 1, S3-S5.
116. Landin, K., Stigendal, L., Eriksson, E., Krotkiewski, M., Risberg, B., Tengborn, L., and Smith, U. 1990. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism, 39: 1044-1048. doi:10.1016/0026-0495(90)90164-8.
117. Lau, D.C., Dhillon, B., Yan, H., Szmitko, P.E., and Verma, S. 2005. Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. 288: H2031-H2041. doi:10.1152/ajpheart.01058.2004.
118. Lee, G.H., Proenca, R., Montez, J.M., Carroll, K.M., Darvishzadeh, J.G., Lee, J.I., and Friedman, J.M. 1996. Abnormal splicing of the leptin receptor in diabetic mice. Nature (London), 379: 632-635. doi:10.1038/379632a0.
119. Lee, J.H., Chan, J.L., Yiannakouris, N., Kontogianni, M., Estrada, E., Seip, R., Orlova, C., and Mantzoros, C.S. 2003. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab. 88: 4848-4856. doi:10.1210/jc.2003-030519.
120. Lee, J.H., Chan, J.L., Sourlas, E., Raptopoulos, V., and Mantzoros, C.S. 2006. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91: 2605-2611. doi:10.1210/jc.2005-1545.
121. Linscheid, P., Seboek, D., Zulewski, H., Keller, U., and Muller, B. 2005. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology, 146: 2699-2708. doi:10.1210/en.2004-1424.
122. Lord, G.M., Matarese, G., Howard, J.K., Baker, R.J., Bloom, S.R., and Lechler, R.I. 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature (London), 394: 897-901.
123. Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., and Matsubara, K. 1996. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 221: 286-289. doi:10.1006/bbrc.1996.0587.
124. Maeda, K., Okubo, K., Shimomura, I., Mizuno, K., Matsuzawa, Y., and Matsubara, K. 1997. Analysis of an expression profile of genes in the human adipose tissue. Gene, 190: 227-235. doi:10.1016/S0378-1119(96)00730-5.
125. Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8: 731-737. doi:10.1038/nm724.
126. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., et al. 2001. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 50: 2094-2099.
127. Martinez, A., Weaver, C., Lopez, J., Bhathena, S.J., Elsasser, T.H., Miller, M.J., et al. 1996. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology, 137: 2626-2632. doi:10.1210/en.137.6.2626.
128. Martinez, A., Elsasser, T.H., Bhathena, S.J., Pio, R., Buchanan, T.A., Macri, C.J., and Cuttitta, F. 1999. Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides, 20: 1471-1478. doi:10.1016/S0196- 9781(99)00158-8.
129. Maslowska, M., Scantlebury, T., Germinario, R., and Cianflone, K. 1997a. Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. J. Lipid Res. 38: 1-11.
130. Maslowska, M., Sniderman, A.D., Germinario, R., and Cianflone, K. 1997b. ASP stimulates glucose transport in cultured human adipocytes. Int. J. Obes. Relat. Metab. Disord. 21: 261-266. doi:10.1038/sj.ijo. 0800396.
131. Maslowska, M., Wang, H.W., and Cianflone, K. 2005. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam. Horm. 70: 309-332.
132. McLaughlin, T., Abbasi, F., Lamendola, C., Liang, L., Reaven, G., Schaaf, P., and Reaven, P. 2002. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation, 106: 2908-2912. doi:10.1161/01.CIR.0000041046.32962.86.
133. McTiernan, A. 2005. Obesity and cancer: the risks, science, and potential management strategies. Oncology, 19: 871-881(Williston Park).
134. Mehta, P.K., and Griendling, K.K. 2006. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. In press. doi:10.1152/ajpcell.00287.2006.
135. Minami, J., Nishikimi, T., Ishimitsu, T., Makino, Y., Kawano, Y., Takishita, S., Kangawa, K., and Matsuoka, H. 2000. Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides in obese patients with essential hypertension. J. Cardiovasc. Pharmacol. 36(Suppl. 2): S83-S86. doi:10.1097/00005344-200000006-00018.
136. Mingrone, G., Rosa, G., Di Rocco, P., Manco, M., Capristo, E., Castagneto, M., et al. 2002. Skeletal muscle triglycerides lowering is associated with net improvement of insulin sensitivity, TNF-α reduction and GLUT4 expression enhancement. Int. J. Obes. Relat. Metab. Disord. 26: 1165-1172. doi:10.1038/sj.ijo.0802053.
137. Minokoshi, Y., Kahn, C.R., and Kahn, B.B. 2003. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J. Biol. Chem. 278: 33609-33612. doi:10.1074/jbc.R300019200.
138. Modur, V., Li, Y., Zimmerman, G.A., Prescott, S.M., and McIntyre, T.M. 1997. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor α. J. Clin. Invest. 100: 2752-2756.
139. Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D.R., Miles, J.M., Yudkin, J.S., Klein, S., and Coppack, S.W. 1997. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J. Clin. Endocrinol. Metab. 82: 4196-4200. doi:10.1210/jc.82.12.4196.
140. Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H., Wareham, N.J., et al. 1997. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature (London), 387: 903-908.
141. Morash, B.A., Willkinson, D., Ur, E., and Wilkinson, M. 2002. Resistin expression and regulation in mouse pituitary. FEBS Lett. 526: 26-30. doi:10.1016/S0014-5793(02)03108-3.
142. Morash, B.A., Ur, E., Wiesner, G., Roy, J., and Wilkinson, M. 2004. Pituitary resistin gene expression: effects of age, gender and obesity. Neuroendocrinology, 79: 149-156. doi:10.1159/000077273.
143. Muller, G., Ertl, J., Gerl, M., and Preibisch, G. 1997. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J. Biol. Chem. 272: 10585-10593.
144. Muoio, D.M., and Newgard, C.B. 2006. Obesity-related derangements in metabolic regulation. Annu. Rev. Biochem. 75: 367-401. doi:10.1146/annurev.biochem.75.103004.142512.
145. Murray, I., Sniderman, A.D., and Cianflone, K. 1999a. Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. Am. J. Physiol. 277: E474-E480.
146. Murray, I., Sniderman, A.D., and Cianflone, K. 1999b. Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J. Lipid Res. 40: 1671-1676.
147. Murray, I., Sniderman, A.D., Havel, P.J., and Cianflone, K. 1999c. Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J. Biol. Chem. 274: 36219-36225. doi:10.1074/jbc.274.51.36219.
148. Must, A., and Strauss, R.S. 1999. Risks and consequences of childhood and adolescent obesity. Int. J. Obes. Relat. Metab. Disord. 23(Suppl. 2): S2-S11. doi:10.1038/sj.ijo.0800852.
149. Nagaev, I., and Smith, U. 2001. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun. 285: 561-564. doi:10.1006/bbrc.2001.5173.
150. Nakamura, T., Honda, K., Ishikawa, S., Kitamura, K., Eto, T., and Saito, T. 1998. Plasma adrenomedullin levels in patients with non-insulin dependent diabetes mellitus: close relationships with diabetic complications. Endocr. J. 45: 241-246.
151. Nambu, T., Arai, H., Komatsu, Y., Yasoda, A., Moriyama, K., Kanamoto, N., Itoh, H., and Nakao, K. 2005. Expression of the adrenomedullin gene in adipose tissue. Regul. Pept. 132: 17-22. doi:10.1016/j.regpep.2005.07.006.
152. Nishizawa, H., Shimomura, I., Kishida, K., Maeda, N., Kuriyama, H., Nagaretani, H., et al. 2002. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 51: 2734-2741.
153. Nonogaki, K., Fuller, G.M., Fuentes, N.L., Moser, A.H., Staprans, I., Grunfeld, C., and Feingold, K.R. 1995. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology, 136: 2143-2149. doi:10.1210/en.136.5.2143.
154. Nuki, C., Kawasaki, H., Kitamura, K., Takenaga, M., Kangawa, K., Eto, T., and Wada, A. 1993. Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. Biochem. Biophys. Res. Commun. 196: 245-251. doi:10.1006/bbrc.1993.2241.
155. Ohashi, K., Kihara, S., Ouchi, N., Kumada, M., Fujita, K., Hiuge, A., et al. 2006. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension, 47: 1108-1116. doi:10.1161/01.HYP.0000222368.43759.a1.
156. Oral, E.A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., et al. 2002. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346: 570-578. doi:10.1056/ NEJMoa012437.
157. Oral, E.A., Javor, E.D., Ding, L., Uzel, G., Cochran, E.K., Young, J.R., et al. 2006. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J. Clin. Endocrinol. Metab. 91: 621-628.
158. Ort, T., Arjona, A.A., MacDougall, J.R., Nelson, P.J., Rothenberg, M.E., Wu, F., Eisen, A., and Halvorsen, Y.D. 2005. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology, 146: 2200-2209. doi:10.1210/en.2004-1421.
159. Otero, M., Lago, R., Gomez, R., Dieguez, C., Lago, F., Gomez-Reino, J., and Gualillo, O. 2006a. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford), 45: 944-950. doi:10.1093/rheumatology/kel157.
160. Otero, M., Lago, R., Gomez, R., Lago, F., Gomez-Reino, J.J., and Gualillo, O. 2006b. Leptin: a metabolic hormone that functions like a proinflammatory adipokine. Drug News Perspect. 19: 21-26. doi:10.1358/dnp.2006.19.1.966243.
161. Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K., Kuriyama, H., et al. 2000. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation, 102: 1296-1301.
162. Pagano, C., Pilon, C., Olivieri, M., Mason, P., Fabris, R., Serra, R., et al. 2006. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J. Clin. Endocrinol. Metab. 91: 3165-3170. doi:10.1210/ jc.2006-0361.
163. Pajvani, U.B., Trujillo, M.E., Combs, T.P., Iyengar, P., Jelicks, L., Roth, K.A., Kitsis, R.N., and Scherer, P.E. 2005. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat. Med. 11: 797-803. doi:10.1038/nm1262.
164. Palanivel, R., Maida, A., Liu, Y., and Sweeney, G. 2006. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia, 49: 183-190. doi:10.1007/s00125-005-0060-z.
165. Path, G., Bornstein, S.R., Gurniak, M., Chrousos, G.P., Scherbaum, W.A., and Hauner, H. 2001. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J. Clin. Endocrinol. Metab. 86: 2281-2288. doi:10.1210/jc.86.5.2281.
166. Paulmyer-Lacroix, O., Desbriere, R., Poggi, M., Achard, V., Alessi, M.C., Boudouresque, F., et al. 2006. Expression of adrenomedullin in adipose tissue of lean and obese women. Eur. J. Endocrinol. 155: 177-185. doi:10.1530/eje.1.02170.
167. Peake, P.W., O'Grady, S., Pussell, B.A., and Charlesworth, J.A. 1997. Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur. J. Clin. Invest. 27: 922-927. doi:10.1046/j.1365-2362.1997.2090759.x.
168. Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, D., Boone, T., and Collins, F. 1995. Effects of the obese gene product on body weight regulation in ob/ob mice. Science (Washington, D.C.), 269: 540-543. doi:10.1126/science.7624776.
169. Pender, J.R., and Pories, W.J. 2005. Epidemiology of obesity in the United States. Gastroenterol. Clin. North Am. 34: 1-7. doi:10. 1016/j.gtc.2004.12.010.
170. Peters, M., Meyer zum Buschenfelde, K.H., and Rose-John, S. 1996. The function of the soluble IL-6 receptor in vivo. Immunol. Lett. 54: 177-184. doi:10.1016/S0165-2478(96)02669-7.
171. Pfutzner, A., Langenfeld, M., Kunt, T., Lobig, M., and Forst, T. 2003. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin. Lab. 49: 571-576.
172. Pinhas-Hamiel, O., and Zeitler, P. 2000. "Who is the wise man? - The one who foresees consequences:". Childhood obesity, new associated comorbidity and prevention. Prev. Med. 31: 702-705. doi:10.1006/pmed. 2000.0752.
173. Pischon, T., Girman, C.J., Hotamisligil, G.S., Rifai, N., Hu, F.B., and Rimm, E.B. 2004. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 291: 1730-1737. doi:10.1001/jama.291.14.1730.
174. Pizzuti, A., Argiolas, A., Di Paola, R., Baratta, R., Rauseo, A., Bozzali, M., et al. 2002. An ATG repeat in the 3′-untranslated region of the human resistin gene is associated with a decreased risk of insulin resistance. J. Clin. Endocrinol. Metab. 87: 4403-4406. doi:10.1210/JC.2002-020096.
175. Poirier, P., Giles, T.D., Bray, G.A., Hong, Y., Stern, J.S., Pi-Sunyer, F.X., and Eckel, R.H. 2006a. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 26: 968-976.
176. Poirier, P., Giles, T.D., Bray, G.A., Hong, Y., Stern, J.S., Pi-Sunyer, F.X., and Eckel, R.H. 2006b. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation, 113: 898-918. doi:10.1161/CIRCULATIONAHA.106. 171016.
177. Popkin, B.M., Kim, S., Rusev, E.R., Du, S., and Zizza, C. 2006. Measuring the full economic costs of diet, physical activity and obesity-related chronic diseases. Obes. Rev. 7: 271-293. doi:10.1111/j.1467-789X.2006.00230.x.
178. Primrose, J.N., Davies, J.A., Prentice, C.R., Hughes, R., and Johnston, D. 1992. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb. Haemost. 68: 396-399.
179. Qi, Y., Takahashi, N., Hileman, S.M., Patel, H.R., Berg, A.H., Pajvani, U.B., Scherer, P.E., and Ahima, R.S. 2004. Adiponectin acts in the brain to decrease body weight. Nat. Med. 10: 524-529. doi:10.1038/nm1029.
180. Quyyumi, A. A. 2006. Women and ischemic heart disease: pathophysiologic implications from the Women's Ischemia Syndrome Evaluation (WISE) Study and future research steps. J. Am. Coll. Cardiol. 47: S66-S71. doi:10.1016/j.jacc.2004.11.075.
181. Ran, J., Hirano, T., Fukui, T., Saito, K., Kageyama, H., Okada, K., and Adachi, M. 2006. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism, 55: 478-488. doi:10.1016/j.metabol.2005.10.009.
182. Reaven, G.M. 2003. The insulin resistance syndrome. Curr. Atheroscler. Rep. 5: 364-371.
183. Rega, G., Kaun, C., Weiss, T.W., Demyanets, S., Zorn, G., Kastl, S.P., et al. 2005. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation, 111: 1938-1945. doi:10.1161/01.CIR.0000161823.55935.BE.
184. Ridker, P.M. 2004. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am. Heart J. 148: S19-S26. doi:10.1016/j.ahj.2004.04.028.
185. Rotter, V., Nagaev, I., and Smith, U. 2003. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-a, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278: 45777-45784. doi:10.1074/jbc.M301977200.
186. Roytblat, L., Rachinsky, M., Fisher, A., Greemberg, L., Shapira, Y., Douvdevani, A., and Gelman, S. 2000. Raised interleukin-6 levels in obese patients. Obes. Res. 8: 673-675.
187. Saleh, J., Blevins, J.E., Havel, P.J., Barrett, J.A., Gietzen, D.W., and Cianflone, K. 2001. Acylation stimulating protein (ASP) acute effects on postprandial lipemia and food intake in rodents. Int. J. Obes. Relat. Metab. Disord. 25: 705-713. doi:10.1038/sj.ijo.0801613.
188. Samad, F., Yamamoto, K., and Loskutoff, D.J. 1996. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-α and lipopolysaccharide. J. Clin. Invest. 97: 37-46.
189. Samad, F., Yamamoto, K., Pandey, M., and Loskutoff, D.J. 1997. Elevated expression of transforming growth factor-β in adipose tissue from obese mice. Mol. Med. 3: 37-48.
190. Samad, F., Pandey, M., and Loskutoff, D.J. 1998. Tissue factor gene expression in the adipose tissues of obese mice. Proc. Natl. Acad. Sci. U.S.A. 95: 7591-7596. doi:10.1073/pnas.95.13.7591.
191. Samaha, F.F., Szapary, P.O., Iqbal, N., Williams, M.M., Bloedon, L.T., Kochar, A., Wolfe, M.L., and Rader, D.J. 2006. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26: 624-630.
192. Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S., and McNiece, I. 1994. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14: 1431-1437.
193. Sawdey, M.S., and Loskutoff, D.J. 1991. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J. Clin. Invest. 88: 1346-1353.
194. Scherer, P.E., Williams, S., Fogliano, M., Baldini, G., and Lodish, H.F. 1995. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270: 26746-26749.
195. Schobitz, B., Voorhuis, D.A., and De Kloet, E.R. 1992. Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Neurosci. Lett. 136: 189-192. doi:10.1016/0304-3940(92)90046-A.
196. Schrauwen, P., Hesselink, M.K., Jain, M., and Cianflone, K. 2005. Acylation-stimulating protein: effect of acute exercise and endurance training. Int. J. Obes. (Lond.), 29: 632-638. doi:10.1038/sj.ijo.0802949.
197. Seidell, J.C. 1995. The impact of obesity on health status: some implications for health care costs. Int. J. Obes. Relat. Metab. Disord. 19(Suppl. 6): S13-S16.
198. Seip, M., and Trygstad, O. 1996. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr. Suppl. 413: 2-28.
199. Shepherd, P.R., and Kahn, B.B. 1999. Glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus. N. Engl. J. Med. 341: 248-257. doi:10.1056/NEJM199907223410406.
200. Shimabukuro, M., Higa, N., Asahi, T., Oshiro, Y., Takasu, N., Tagawa, T., et al. 2003. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metab. 88: 3236-3240. doi:10.1210/jc.2002- 021883.
201. Shimomura, I., Funahashi, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., et al. 1996. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 2: 800-803. doi:10.1038/nm0796-800.
202. Shimosawa, T., Ogihara, T., Matsui, H., Asano, T., Ando, K., and Fujita, T. 2003. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension, 41: 1080-1085. doi:10.1161/01.HYP. 0000066846.46422.2C.
203. Silswal, N., Singh, A.K., Aruna, B., Mukhopadhyay, S., Ghosh, S., and Ehtesham, N.Z. 2005. Human resistin stimulates the proinflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem. Biophys. Res. Commun. 334:1092-1101.doi:10.1016/j.bbrc.2005.06.202.
204. Skurk, T., van Harmelen, V., Blum, W.F., and Hauner, H. 2005. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes. Res. 13: 969-973.
205. Skurk, T., van Harmelen, V., Lee, Y.M., Wirth, A., and Hauner, H. 2002. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. Horm. Metab. Res. 34: 659-663. doi:10.1055/s-2002-38253.
206. Smith, S.R., Bai, F., Charbonneau, C., Janderova, L., and Argyropoulos, G. 2003. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes, 52: 1611-1618.
207. Sniderman, A.D., Cianflone, K.M., and Eckel, R.H. 1991. Levels of acylation stimulating protein in obese women before and after moderate weight loss. Int. J. Obes. 15: 333-336.
208. Stephens, J.M., and Vidal-Puig, A.J. 2006. An update on visfatin/ pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr. Opin. Lipidol. 17: 128-131.
209. Steppan, C.M., and Lazar, M.A. 2002. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 13: 18-23.
210. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., et al. 2001. The hormone resistin links obesity to diabetes. Nature (London), 409: 307-312. doi:10.1038/35053000.
211. Strassmann, G., Fong, M., Kenney, J.S., and Jacob, C.O. 1992. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89: 1681-1684.
212. Sugo, S., Minamino, N., Kangawa, K., Miyamoto, K., Kitamura, K., Sakata, J., Eto, T., and Matsuo, H. 1994a. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem. Biophys. Res. Commun. 201: 1160-1166. doi:10.1006/bbrc.1994.1827.
213. Sugo, S., Minamino, N., Shoji, H., Kangawa, K., Kitamura, K., Eto, T., and Matsuo, H. 1994b. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun. 203: 719-726. doi: 0.1006/bbrc.1994.2241.
214. Szapary, P.O., Bloedon, L.T., Samaha, F.F., Duffy, D., Wolfe, M.L., Soffer, D., et al. 2006. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26: 182-188.
215. Tanko, L.B., Bruun, J.M., Alexandersen, P., Bagger, Y.Z., Richelsen, B., Christiansen, C., and Larsen, P.J. 2004. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation, 110: 2246-2252. dor.10.1161/01.CIR.0000144470.55149.E5.
216. Tao, Y., Cianflone, K., Sniderman, A.D., Colby-Germinario, S.P., and Germinario, R.J. 1997. Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim. Biophys. Acta, 1344: 221-229.
217. Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., et al. 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell, 83: 1263-1271. doi:10.1016/0092-8674(95)90151-5.
218. Teng, B., Forse, A., Rodriguez, A., and Sniderman, A. 1988. Adipose tissue glyceride synthesis in patients with hyperapobetalipoproteinemia. Can. J. Physiol. Pharmacol. 66: 239-242.
219. Torti, F.M., Dieckmann, B., Beutler, B., Cerami, A., and Ringold, G.M. 1985. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (Washington, D.C.), 229: 867-869. doi:10.1126/science.3839597.
220. Tovar, S., Nogueiras, R., Tung, L.Y., Castaneda, T.R., Vazquez, M.J., Morris, A., et al. 2005. Central administration of resistin promotes short-term satiety in rats. Eur. J. Endocrinol. 153: R1-R5. doi:10.1530/eje.1.01999.
221. Tremblay, M.S., Katzmarzyk, P.T., and Willms, J.D. 2002. Temporal trends in overweight and obesity in Canada, 1981-1996. Int. J. Obes. Relat. Metab. Disord. 26: 538-543. doi:10.1038/sj.ijo.0801923.
222. Van Harmelen, V., Reynisdottir, S., Cianflone, K., Degerman, E., Hoffstedt, J., Nilsell, K., Sniderman, A., and Arner, P. 1999. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J. Biol. Chem. 274: 18243-18251. doi:10.1074/jbc. 274.26.18243.
223. Van Heek, M., Compton, D.S., France, C.F., Tedesco, R.P., Fawzi, A.B., Graziano, M.P., et al. 1997. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest. 99: 385-390.
224. Waki, H., Yamauchi, T., Kamon, J., Ito, Y., Uchida, S., Kita, S., et al. 2003. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J. Biol. Chem. 278: 40352-40363. doi:10.1074/jbc.M300365200.
225. Wallenius, V., Wallenius, K., Ahren, B., Rudling, M., Carlsten, H., Dickson, S.L., Ohlsson, C., and Jansson, J.O. 2002. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8: 75-79. doi:10.1038/nm0102-75.
226. Walsh, M.J., Sniderman, A.D., Cianflone, K., Vu, H., Rodriguez, M.A., and Forse, R.A. 1989. The effect of ASP on the adipocyte of the morbidly obese. J. Surg. Res. 46: 470-473. doi:10.1016/00224804(89)90162-5.
227. Wang, H., Chu, W.S., Hemphill, C., and Elbein, S.C. 2002. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J. Clin. Endocrinol. Metab. 87: 2520-2524. doi:10.1210/jc.87.6.2520.
228. Wang, M.Y., Orci, L., Ravazzola, M., and Unger, R.H. 2005. Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. Proc. Natl. Acad. Sci. U.S.A. 102: 18011-18016. doi:10.1073/pnas.0509001102.
229. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W., Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112: 1796-1808. doi:10.1172/ JCI200319246.
230. Whitehead, J.P., Richards, A.A., Hickman, I.J., Macdonald, G.A., and Prins, J.B. 2006. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes. Metab. 8: 264-280. doi:10.1111/j.1463-1326.2005.00510.x.
231. Wilcox, G. 2005. Insulin and insulin resistance. Clin. Biochem. Rev. 26: 19-39.
232. Wilkinson, M., Wilkinson, D., Wiesner, G., Morash, B., and Ur, E. 2005. Hypothalamic resistin immunoreactivity is reduced by obesity in the mouse: co-localization with α-melanostimulating hormone. Neuroendocrinology, 81: 19-30. doi:10.1159/000084871.
233. Wolk, R., and Somers, V.K. 2006. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes. Metab. 8: 250-260. doi:10.1111/j.1463-1326.2005.00508.x.
234. Xia, Z., Sniderman, A.D., and Cianflone, K. 2002. Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J. Biol. Chem. 277: 45874-45879. doi:10.1074/jbc.M207281200.
235. Xu, H., Hirosumi, J., Uysal, K.T., Guler, A.D., and Hotamisligil, G.S. 2002. Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology, 143: 1502-1511. doi:10.1210/en.143.4.1502.
236. Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830. doi:10.1172/JCI200319451.
237. Xu, A., Chan, K.W., Hoo, R.L., Wang, Y., Tan, K.C., Zhang, J., et al. 2005. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J. Biol. Chem. 280: 18073-18080.
238. Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., et al. 2003a. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (London), 423: 762-769. doi:10.1038/ nature01705.
239. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8: 1288-1295. doi:10.1038/nm788.
240. Yamauchi, T., Kamon, J., Waki, H., Imai, Y., Shimozawa, N., Hioki, K., et al. 2003b. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 278: 2461-2468. doi:10.1074/jbc.M209033200.
241. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7: 941-946. doi:10.1038/90984.
242. Yang, R.Z., Huang, Q., Xu, A., McLenithan, J.C., Eisen, J.A., Shuldiner, A.R., Alkan, S., and Gong, D.W. 2003. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem. Biophys. Res. Commun. 310: 927-935. doi:10.1016/j.bbrc.2003.09.093.
243. Yang, Q., Graham, T.E., Mody, N., Preitner, F., Peroni, O.D., Zabolotny, J.M., et al. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature (London), 436: 356-362. doi:10.1038/nature03711.
244. Yang, Y., Lu, H.L., Zhang, J., Yu, H.Y., Wang, H.W., Zhang, M.X., and Cianflone, K. 2006. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs. obese type 2 diabetes. Int. J. Obes. (Lond.), 30: 439-446. doi:10.1038/sj.ijo.0803173.
245. Yasruel, Z., Cianflone, K., Sniderman, A.D., Rosenbloom, M., Walsh, M., and Rodriguez, M.A. 1991. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids, 26: 495-499. doi:10.1007/BF02536592.
246. Yin, W.H., Jen, H.L., Chen, J.W., Lin, S.J., and Young, M.S. 2006. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab. 32: 229-235.
247. Yu, J.G., Javorschi, S., Hevener, A.L., Kruszynska, Y.T., Norman, R.A., Sinha, M., and Olefsky, J.M. 2002. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes, 51: 2968-2974.
248. Yudkin, J.S., Stehouwer, C.D., Emeis, J.J., and Coppack, S.W. 1999. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19: 972-978.
249. Zelissen, P.M., Stenlof, K., Lean, M.E., Fogteloo, J., Keulen, E.T., Wilding, J., et al. 2005. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes. Metab. 7: 755-761. doi:10.1111/j.1463-1326.2005.00468.x.
250. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature (London), 372: 425-432. doi:10.1038/372425a0.
251. Zhang, B., Graziano, M.P., Doebber, T.W., Leibowitz, M.D., White-Carrington, S., Szalkowski, D.M., et al. 1996. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J. Biol. Chem. 271: 9455-9459.
252. Ziccardi, P., Nappo, F., Giugliano, G., Esposito, K., Marfella, R., Cioffi, M., et al. 2002. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation, 105: 804-809. doi:10.1161/hc0702.104279.